Patent Law Weblog
recent posts
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
- United States Files Statement of Interest in Patent Infringement Proceedings
about
Month: March 2011
-
By Kevin E. Noonan — Senate bill S. 23 (the "America Invents Act") contains several provisions changing the statutory authority of the U.S. Patent and Trademark Office (falling short, fortunately, of giving the Office substantive rule-making authority). The most far-reaching of these changes is contained in Section 9, which gives the Office (for the first…
-
By James DeGiulio — When Andrew Fire and Craig Mello (at right) unraveled the mechanism of RNA interference (RNAi) and were awarded the Nobel Prize in 2006 for their efforts, RNAi was predicted to become the next great source of new therapeutics. Pharmaceutical companies moved quickly to devote research funding and personnel to developing what…
-
By Kevin E. Noonan — Seante bill S. 23 (the "America Invents Act"), as passed on March 13, 2011, contains few provisions related to aspects of patent law administered by the judiciary. This is ironic, in view of the extent to which calls for reform of damages, venue, willfulness, and other issues provided a major…
-
By Donald Zuhn — Last week, the U.S. Patent and Trademark Office announced that it would be offering relief to persons affected by the 9.0-magnitude earthquake that struck about 250 miles northeast of Tokyo on March 11 and the resulting tsunami. In particular, the Office stated that it would withdraw and reissue any outstanding Office…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. Glycobiosciences, Inc. v. Nycomed US, Inc. et al.2:11-cv-01280; filed March 17, 2011 in the Eastern District of New York • Plaintiff: Glycobiosciences, Inc.• Defendants: Nycomed US, Inc.; Pharmaderm; Jagotec AG Infringement of U.S. Patent Nos.…
-
March 23, 2011 – Antibody Patents after Centocor (Intellectual Property Owners Association) – 2:00 PM (ET) April 5-6, 2011 – International Patent Forum 2011 (Managing Intellectual Property) – London, UK April 6-9, 2011 – 26th Annual Intellectual Property Law Conference (American Bar Association Section of Intellectual Property Law) – Arlington, VA April 13-15, 2011 –…
-
The Biotechnology Industry Organization (BIO) will be holding its Intellectual Property Counsels Committee (IPCC) Spring Conference & Meeting on April 13-15, 2011 in Seattle, WA. The semi-annual IPCC conference will once again be open to the public. The conference will offer presentations on the following topics: Wednesday, April 13: • Supreme Court Practice: An Insider's…
-
The Intellectual Property Owners Association (IPO) will offer a one-hour webinar entitled "Antibody Patents after Centocor" on Wednesday, March 23, 2011 beginning at 2:00 PM (ET). The IPO webinar will examine how much descrioption is enough when it comes to written description for antibody patents as well as discuss the obviousness challenges antibody patents face…
-
By Kevin E. Noonan — S. 23 (the "America Invents Act" or, colloquially the patent reform bill) contains additional provisions for the U.S. Patent Office to obtain information related to patentability, both pre- and post-grant, as well as establishing a replacement for the Board of Patent Appeals and Interferences called the Patent Trial and Appeal…
-
By Kevin E. Noonan — The "America Invents Act" (S. 23 or the patent reform bill) passed by the Senate contains revisions to current inter partes reexamination as well as provisions for an entirely new post-grant review proceeding. Section 5(a) sets forth the revisions to inter partes reexamination. The most significant of these is a…
Patent Docs 